Apoptone: Phase I/IIa completed

Harbor completed an open-label, U.S. Phase I/IIa trial evaluating 10-700 mg/day Apoptone in 68 patients. Last September, Harbor reported data from 22 chemotherapy-naïve patients showing that 100 or 35...